Compass Pathways (FRA:5Y6) Beta: 4.1249 (As of Jun. 30, 2026)


FRA:5Y6 Compass Pathways PLC FRA:5Y6
40 GF Score
Price €12.70
! 2 Warning Signs
View Full Analysis

What is Compass Pathways Beta?

Compass Pathways FRA:5Y6 -4.51% 40 Beta is 4.1249 as of Jun. 30, 2026. GuruFocus rates FRA:5Y6 with a GF Score™ of 40/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-30), Compass Pathways's Beta is 4.1249.


Compass Pathways  (FRA:5Y6) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Compass Pathways Beta Related Terms


Compass Pathways Beta Historical Data

* Premium members only.

The historical data trend for Compass Pathways's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Pathways Beta Chart

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 1.95 -0.44 0.32

Compass Pathways Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 2.38 2.49 0.32 2.76

FRA:5Y6 vs AGL, MD, SEM: Beta Comparison

For the Medical Care Facilities subindustry, Compass Pathways's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compass Pathways Beta vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Beta distribution charts can be found below:

* The bar in red indicates where Compass Pathways's Beta falls into.


FRA:5Y6
40GF Score
Compass Pathways PLC FRA:5Y6
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Pathways Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 4.1249 mean?
Compass Pathways (FRA:5Y6) has a Beta of 4.1249 as of Jun. 30, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Compass Pathways and its competitors.
Is Compass Pathways' Beta too high?
Compass Pathways' current Beta is 4.1249. Overall, Compass Pathways has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' Beta compare to AGL and MD?
Compass Pathways' Beta of 4.1249 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Compass Pathways and its competitors. Compass Pathways's current Beta is 4.1249. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (FRA:5Y6) has a current Beta of 4.1249. The current Beta is 4.1249. Compass Pathways' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Compass Pathways (FRA:5Y6), the current Beta is 4.1249 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Pathways Business Description

Address 33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
40GF Score

Get the complete analysis for FRA:5Y6

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.70
Price